Q-omics provides the consensus-scored SPG7 profile across patient tissues and cancer cell-line models. SPG7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPG7 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SPG7 protein abundance shows 20,110 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where SPG7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPG7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPG7 survival associations across molecular data types. SPG7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPG7 RNA expression–survival associations across cancer types. High SPG7 expression shows unfavorable associations in KIRC, ACC and SKCM, but favorable associations in KIRP, BLCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPG7 RNA expression.
This table summarizes SPG7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SPG7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPG7 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, STAD, COAD and CHOL. The THCA box plot shows higher SPG7 RNA expression in normal versus tumor tissue (log2 FC = −0.711, t-test p < 0.001).
This table shows molecular features associated with SPG7 in patient tissues and cancer cell lines. In patient samples, SPG7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPG7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
